+ Watch LXRX
on My Watchlist
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
When Lexicon's cap goes over a billion bucks, something just doesn't ring right to me. I can't help but think that a lot of people buying this stub think it's a cheap stock because of the share price and don't really pay attention to the share count. The company reported some encouraging data for LX4211 and telotristat in 2012, but I don't see any likely catalysts in the near future. Cash is 200M, but burn is 30M so that runway is only good until mid 2014. Expect ongoing substantial dilutive financings and further ballooning of the share count. Once the phony fiscal cliff enthusiasm gives way to renewed knee quivering in the face of economic reality, expect bloated stocks like Lexicon to be the first to give up their gains. If this stock continues its cyclical pattern, I might be writing my next opinion from the score leader box.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions